Search

Displaying results 4421 - 4430 of 5300 in total
  1. Drug

    Beta-(1,3)-D glucan

    go.drugbank.com/drugs/DB16468
    Investigational

  2. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan is an intravenous endothelin receptor A/B antagonist.

  3. Drug

    Talacotuzumab

    go.drugbank.com/drugs/DB14796
    Investigational

    Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.

  4. Drug

    COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB16520
    Experimental

    COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen

  5. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  6. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

  7. Drug

    Inodiftagene vixteplasmid

    go.drugbank.com/drugs/DB16017
    Investigational

    Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed

  8. Drug

    Lofentanil

    go.drugbank.com/drugs/DB09174
    ExperimentalIllicit

    Lofentanil is an analog of fentanyl and is one of the most potent opioids available today.

  9. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the ...

  10. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).